Clinical Trial Update: Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating temozolomide or selumetinib for metastatic melanoma of the eye (uveal/iris melanoma) has completed, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iris Melanoma
• Ocular Melanoma with Extraocular Extension
• Posterior Uveal Melanoma
• Uveal Melanoma

Drugs mentioned

• Selumetinib (selumetinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-18